Active	Status	Sponsor type	Region	Phase	Filter
1 Active 7 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
CP-870893 / Pfizer
ACTRN12609000294257: CD-40 activating antibody (CP-870,893) in combination with cisplatin and pemetrexed in unresectable malignant mesothelioma: a phase Ib study	Completed	1	15			Sir Charles Gairdner Hospital, Pfizer Australia (research grant-in-aid for investigator initiated study)	unresectable malignant pleural mesothelioma